Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Kensey Nash Looking At Smaller Angio-Seal To Boost Market Share

This article was originally published in The Gray Sheet

Executive Summary

Kensey Nash is predicting that the U.S. launch in January of a 6 Fr version of its Angio-Seal hemostatic puncture closure device will give the company a leg up on competitors Datascope (VasoSeal) and Perclose (ProStar and TechStar).

You may also be interested in...



St. Jude's $167 Mil. Angio-Seal Puncture Closure Buy Adds $50 Mil. In Sales

St. Jude's $167 mil. cash acquisition of marketing and manufacturing rights to Kensey Nash's Angio-Seal hemostatic puncture closure device from Tyco International would "more than double" sales into the cardiology cath lab by St. Jude's Daig division and add 60 to its sales and marketing staff, the firm states.

Moderna Files COVID-19 Vaccine After Second Impressive Read-Out

Second read-out maintains 94% level of efficacy, with a very early signal that it could outperform Pfizer’s rival mRNA candidate in preventing severe cases.

Sanofi's Dupixent Cleared For Children With Atopic Dermatitis In EU

The French major and Regeneron have racked up another indication for Dupixent with the blockbuster getting approval in Europe to treat children with severe eczema.

UsernamePublicRestriction

Register

LL1134478

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel